NO993600L - Behandling av autoimmun sykdom ved Õ bruke "tolerization" i kombinasjon med metotreksat - Google Patents

Behandling av autoimmun sykdom ved Õ bruke "tolerization" i kombinasjon med metotreksat

Info

Publication number
NO993600L
NO993600L NO993600A NO993600A NO993600L NO 993600 L NO993600 L NO 993600L NO 993600 A NO993600 A NO 993600A NO 993600 A NO993600 A NO 993600A NO 993600 L NO993600 L NO 993600L
Authority
NO
Norway
Prior art keywords
methotrexate
combination
autoimmune disease
tolerization
treatment
Prior art date
Application number
NO993600A
Other languages
English (en)
Other versions
NO993600D0 (no
Inventor
Howard L Weiner
Ahmad Al-Sabbagh
Patricia A Nelson
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of NO993600D0 publication Critical patent/NO993600D0/no
Publication of NO993600L publication Critical patent/NO993600L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
    • B41J—TYPEWRITERS; SELECTIVE PRINTING MECHANISMS, i.e. MECHANISMS PRINTING OTHERWISE THAN FROM A FORME; CORRECTION OF TYPOGRAPHICAL ERRORS
    • B41J2/00—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed
    • B41J2/005—Typewriters or selective printing mechanisms characterised by the printing or marking process for which they are designed characterised by bringing liquid or particles selectively into contact with a printing material
    • B41J2/01—Ink jet
    • B41J2/21—Ink jet for multi-colour printing
    • B41J2/2107—Ink jet for multi-colour printing characterised by the ink properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0094—Colour printing
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
    • G06K2215/00—Arrangements for producing a permanent visual presentation of the output data
    • G06K2215/0082—Architecture adapted for a particular function
    • G06K2215/0097—Printing on special media, e.g. labels, envelopes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En kombinasjon en mukøs administrering eller bystander antigen og en oral, enteral eller parenteral administrerbar metotreksat er anvendt for å fremstille en farmasøytisk formulering og for å behandle eller forhindre autoimmun sykdom. Mengdene av bystander antigen og metotreksat er effektiv i kombinasjon for å undetrykke autoimmun respons assosiert med den autoimmune sykdommen.
NO993600A 1997-01-24 1999-07-23 Behandling av autoimmun sykdom ved Õ bruke "tolerization" i kombinasjon med metotreksat NO993600L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3672297P 1997-01-24 1997-01-24
PCT/US1998/001648 WO1998032451A1 (en) 1997-01-24 1998-01-26 Treatment of autoimmune disease using tolerization in combination with methotrexate

Publications (2)

Publication Number Publication Date
NO993600D0 NO993600D0 (no) 1999-07-23
NO993600L true NO993600L (no) 1999-09-23

Family

ID=21890248

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993600A NO993600L (no) 1997-01-24 1999-07-23 Behandling av autoimmun sykdom ved Õ bruke "tolerization" i kombinasjon med metotreksat

Country Status (10)

Country Link
EP (1) EP0994717A4 (no)
JP (1) JP2001511134A (no)
KR (1) KR20000070460A (no)
AU (1) AU6648898A (no)
BR (1) BR9807112A (no)
CA (1) CA2278152A1 (no)
HU (1) HUP0001960A2 (no)
IL (1) IL131025A0 (no)
NO (1) NO993600L (no)
WO (1) WO1998032451A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068290A2 (en) 2002-02-11 2003-08-21 Antares Pharma, Inc. Intradermal injector
BRPI0614025A2 (pt) 2005-01-24 2012-12-25 Antares Pharma Inc injetores de jato
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
WO2009114542A1 (en) 2008-03-10 2009-09-17 Antares Pharma, Inc. Injector safety device
ES2738539T3 (es) 2008-08-05 2020-01-23 Antares Pharma Inc Inyector de dosis múltiples
AU2010226442A1 (en) 2009-03-20 2011-10-13 Antares Pharma, Inc. Hazardous agent injection system
CA2802853C (en) 2010-06-16 2016-07-26 Bruce Chandler May Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
KR20150003179A (ko) 2012-03-06 2015-01-08 안타레스 팔마, 인코퍼레이티드 분리력 특징을 가진 사전충전형 주사기
EP4186545A1 (en) 2012-04-06 2023-05-31 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
WO2013169800A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Injection device with cammed ram assembly
ES2763633T3 (es) 2013-02-11 2020-05-29 Antares Pharma Inc Dispositivo de inyección por chorro asistido por aguja que tiene fuerza de disparo reducida
JP6030803B2 (ja) 2013-03-11 2016-11-24 アンタレス・ファーマ・インコーポレーテッド ピニオンシステムを有する用量注射器
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
MX2015011905A (es) 2013-03-13 2016-01-08 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
WO2014164282A1 (en) 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of traumatic injury
WO2014164299A1 (en) * 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336954C (en) * 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
JPH05507501A (ja) * 1990-09-06 1993-10-28 リックスウーニーベルシテイト・テ・ウットレヒト リンパ球応答と免疫関連疾患との阻害剤
EP0627933B1 (en) * 1992-02-28 2002-11-27 Autoimmune, Inc. Bystander suppression of autoimmune diseases
WO1996040235A1 (en) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Method to use superantigens to target subpopulations of t cells
US6010722A (en) * 1995-06-13 2000-01-04 Nippon Meat Packers, Inc. Oral remedy for rheumatoid arthritis and functional food

Also Published As

Publication number Publication date
AU6648898A (en) 1998-08-18
HUP0001960A2 (hu) 2000-10-28
EP0994717A4 (en) 2000-07-26
WO1998032451A1 (en) 1998-07-30
EP0994717A1 (en) 2000-04-26
CA2278152A1 (en) 1998-07-30
BR9807112A (pt) 2001-09-18
KR20000070460A (ko) 2000-11-25
JP2001511134A (ja) 2001-08-07
NO993600D0 (no) 1999-07-23
IL131025A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
NO993600L (no) Behandling av autoimmun sykdom ved Õ bruke "tolerization" i kombinasjon med metotreksat
AU2634592A (en) Improved interferon therapy
NZ293542A (en) Treatment of bowel microflora to relive neurological disorders
HUT74832A (en) Method and compositions for treatment of autoimmune diseases by use of bystander antigen
ATE282418T1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
EP0957925A4 (en) TREATMENT OF OSTEOARTHRITIS BY ADMINISTRATION OF POLY-N-ACETYL-D-GLUCOSAMINE
CA2170243A1 (fr) Nouvelles utilisations d'un complexe a base de phospholipides cerebraux en therapeutique et dans l'alimentation
王庆其 Advances in treatment of epilepsy with traditional Chinese medicine
孙丽琴 TREATMENT OF RHEU MATOID ARTHRITIS BY WARMING NEEDLE
Maher et al. Commentary: making tuberculosis treatment available for all.
胡军 et al. COMPARISON ON THE CLINICAL EFFECT IN THE TREATMENT OF HYPERTHYROIDISM WITH DIFFERENT ACUPUNCTURE INTERVAL
WO1999038524A3 (en) Therapeutic administration of low density lipoprotein receptor for viral infections and immune regulation
Lavaroni et al. Hallopeau's acrodermatitis treated with cyclosporin Aa case report
胡金生 Acupuncture treatment of epigastric pain
王芳妮 Clinical Observation on Treatment of 120 Cases of Periphery Facial Paralysis with Penetration Needling
李征宇 et al. Observations on the effects of massage on experimental gastric ulcer in rats
葛通远 et al. AN APPROACH TO THE MECHANISMS OF LASER ACUPUNCTURE IN TREATMENT OF EXOPHTHALMIC HYPERTHYROIDISM
魏子孝 Differential TCM Treatment of Hyperthyroidism
杨露 et al. Chloasma Treated Mainly with Facial Acupuncture
施婷 et al. An analysis of the relative specificity of acupoints in sciatica models
邵永金 et al. A survey on acupuncture treatment of peripheral nerve injury
周立群 How to Promote the Therapeutic Effect of Auriculotherapy in the Treatment of Vascular Hypertension?
黄巍 et al. CLINICAL OBSERVATION ON THE TREATMENT OF LUMBAR VERTEBRA HYPEROSTEOGENY WITH ELECTRO-AND HYDRO-ACUPUNCTURE
王征美 et al. CLINICAL STUDIES ON THE TREATMENT OF PARAPLEGIC PATIENTS'PAIN WITH ACUPUNCTURE
胡金生 et al. Acupuncture treatment of sciatica